留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝癌局部治疗——消融或切除?

史瑶平 翟博

史瑶平, 翟博. 肝癌局部治疗——消融或切除?[J]. 临床肝胆病杂志, 2021, 37(3): 506-509. DOI: 10.3969/j.issn.1001-5256.2021.03.003
引用本文: 史瑶平, 翟博. 肝癌局部治疗——消融或切除?[J]. 临床肝胆病杂志, 2021, 37(3): 506-509. DOI: 10.3969/j.issn.1001-5256.2021.03.003
SHI YP, ZHAI B. Local treatment of liver cancer: Ablation or resection?[J]. J Clin Hepatol, 2021, 37(3): 506-509. DOI: 10.3969/j.issn.1001-5256.2021.03.003
Citation: SHI YP, ZHAI B. Local treatment of liver cancer: Ablation or resection?[J]. J Clin Hepatol, 2021, 37(3): 506-509. DOI: 10.3969/j.issn.1001-5256.2021.03.003

肝癌局部治疗——消融或切除?

DOI: 10.3969/j.issn.1001-5256.2021.03.003
基金项目: 

国家自然科学基金 81801800

详细信息
    作者简介:

    史瑶平(1983—),男,主治医师,博士,主要研究肝癌的综合介入及靶向免疫治疗

    通讯作者:

    翟博,zhaiboshi@sina.com

  • 利益冲突声明:所有作者均声明不存在利益冲突。
  • 作者贡献声明:史瑶平负责调研整理文献及起草论文;翟博负责提出文章选题、设计论文框架及修订论文。
  • 中图分类号: R735.7

Local treatment of liver cancer: Ablation or resection?

  • 摘要: 肝癌是我国常见的恶性肿瘤之一,手术切除目前仍然是肝癌患者首选的根治性方法,但大部分患者由于受肿瘤大小及部位、肝功能和整体状况的影响,不能耐受手术切除。近年来,以射频和微波为代表的局部消融技术迅速发展,并在临床中广泛应用,更被誉为堪与外科切除相媲美的肝癌根治性治疗的新技术。就局部消融与外科切除在肝癌治疗中的应用和选择作一简介。
  • [1] GEYIK S, AKHAN O, ABBASOGLU O, et al. Radiofrequency ablation of unresectable hepatic tumors[J]. Diagn Interv Radiol, 2006, 12(4): 195-200. http://www.ncbi.nlm.nih.gov/pubmed/11503676
    [2] POGGI G, TOSORATTI N, MONTAGNA B, et al. Microwave ablation of hepatocellular carcinoma[J]. World J Hepatol, 2015, 7(25): 2578-2589. DOI: 10.4254/wjh.v7.i25.2578
    [3] THANOS, L, POULOU LS, ZIAKAS PD, et al. Image-guided radiofrequency ablation (RFA) of unresectable hepatic tumors using a triple-spiral-shaped electrode needle: Initial experience in 34 patients[J]. Cardiovasc Intervent Radiol, 2010, 33(1): 107-112. DOI: 10.1007/s00270-009-9649-9
    [4] VIBERT E, SCHWARTZ M, OLTHOFF KM. Advances in resection and transplantation for hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2): 262-276. DOI: 10.1016/j.jhep.2019.11.017
    [5] PINNA AD, YANG T, MAZZAFERRO V, et al. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma[J]. Ann Surg, 2018, 268(5): 868-875. DOI: 10.1097/SLA.0000000000002889
    [6] CHACKO S, SAMANTA S. Hepatocellular carcinoma: A life-threatening disease[J]. Biomed Pharmacother, 2016, 84: 1679-1688. DOI: 10.1016/j.biopha.2016.10.078
    [7] OGATA S, BELGHITI J, FARGES O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma[J]. Br J Surg, 2006, 93(9): 1091-1098. DOI: 10.1002/bjs.5341
    [8] ISHIZAWA T, HASEGAWA K, AOKI T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma[J]. Gastroenterology, 2008, 134(7): 1908-1916. DOI: 10.1053/j.gastro.2008.02.091
    [9] FUKS D, DOKMAK S, PARADIS V, et al. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: An intention-to-treat analysis[J]. Hepatology, 2012, 55(1): 132-140. DOI: 10.1002/hep.24680
    [10] BRUIX J, SHERMAN M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma[J]. Hepatology, 2005, 42(5): 1208-1236. DOI: 10.1002/hep.20933
    [11] HUANG J, YAN L, CHENG Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria[J]. Ann Surg, 2010, 252(6): 903-912. DOI: 10.1097/SLA.0b013e3181efc656
    [12] BREEN DJ, LENCIONI R. Image-guided ablation of primary liver and renal tumours[J]. Nat Rev Clin Oncol, 2015, 12(3): 175-186. DOI: 10.1038/nrclinonc.2014.237
    [13] AHMED M, BRACE CL, LEE FT Jr, et al. Principles of and advances in percutaneous ablation[J]. Radiology, 2011, 258(2): 351-369. DOI: 10.1148/radiol.10081634
    [14] YU NC, RAMAN SS, KIM YJ, et al. Microwave liver ablation: Influence of hepatic vein size on heat-sink effect in a porcine model[J]. J Vasc Interv Radiol, 2008, 19(7): 1087-1092. DOI: 10.1016/j.jvir.2008.03.023
    [15] SCHRAMM W, YANG D, WOOD BJ, et al. Contribution of direct heating, thermal conduction and perfusion during radiofrequency and microwave ablation[J]. Open Biomed Eng J, 2007, 1: 47-52. DOI: 10.2174/1874120700701010047
    [16] SHIBATA T, ⅡMURO Y, YAMAMOTO Y, et al. Small hepatocellular carcinoma: Comparison of radio-frequency ablation and percutaneous microwave coagulation therapy[J]. Radiology, 2002, 223(2): 331-337. DOI: 10.1148/radiol.2232010775
    [17] LU MD, XU HX, XIE XY, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: A retrospective comparative study[J]. J Gastroenterol, 2005, 40(11): 1054-1060. DOI: 10.1007/s00535-005-1671-3
    [18] QIAN GJ, WANG N, SHEN Q, et al. Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: Experimental and clinical studies[J]. Eur Radiol, 2012, 22(9): 1983-1990. DOI: 10.1007/s00330-012-2442-1
    [19] YU J, YU XL, HAN ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: A phase Ⅲ randomised controlled trial[J]. Gut, 2017, 66(6): 1172-1173. DOI: 10.1136/gutjnl-2016-312629
    [20] LIU Y, ZHENG Y, LI S, et al. Percutaneous microwave ablation of larger hepatocellular carcinoma[J]. Clin Radiol, 2013, 68(1): 21-26. DOI: 10.1016/j.crad.2012.05.007
    [21] XU LF, SUN HL, CHEN YT, et al. Large primary hepatocellular carcinoma: Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy[J]. J Gastroenterol Hepatol, 2013, 28(3): 456-463. DOI: 10.1111/jgh.12088
    [22] ABDELAZIZ AO, NABEEL MM, ELBAZ TM, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: Prospective analysis[J]. Scand J Gastroenterol, 2015, 50(4): 479-484. DOI: 10.3109/00365521.2014.1003397
    [23] COPPER IS. Cryogenic surgery: A new method of destruction or extirpation of benign or malignant tissues[J]. N Engl J Med, 1963, 268: 743-749. DOI: 10.1056/NEJM196304042681401
    [24] JUNGRAITHMAYR W, BURGER D, OLSCHEWSKI M, et al. Cryoablation of malignant liver tumors: Results of a single center study[J]. Hepatobiliary Pancreat Dis Int, 2005, 4(4): 554-560. http://qikan.cqvip.com/Qikan/Article/Detail?id=1003033805
    [25] SEIFERT JK, MORRIS DL. World survey on the complications of hepatic and prostate cryotherapy[J]. World J Surg, 1999, 23(2): 109-113; discussion 113-114.
    [26] SMITH MT, RAY CE. The treatment of primary and metastatic hepatic neoplasms using percutaneous cryotherapy[J]. Semin Intervent Radiol, 2006, 23(1): 39-46. DOI: 10.1055/s-2006-939840
    [27] BILCHIK AJ, WOOD TF, ALLEGRA D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: A proposed algorithm[J]. Arch Surg, 2000, 135(6): 657-662; discussion 662-664.
    [28] GOLDBERG SN, GRASSI CJ, CARDELLA JF, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria[J]. J Vasc Interv Radiol, 2009, 20(7 Suppl): s377-s390. http://www.sciencedirect.com/science/article/pii/s1051044314008458
    [29] PACELLA CM, BIZZARRI G, FRANCICA G, et al. Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation[J]. J Hepatol, 2006, 44(5): 902-909. DOI: 10.1016/j.jhep.2006.01.031
    [30] FRANCICA G, PETROLATI A, di STASIO E, et al. Effectiveness, safety, and local progression after percutaneous laser ablation for hepatocellular carcinoma nodules up to 4 cm are not affected by tumor location[J]. AJR Am J Roentgenol, 2012, 199(6): 1393-1401. DOI: 10.2214/AJR.11.7850
    [31] PACELLA CM, BIZZARRI G, FRANCICA G, et al. Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: Analysis of factors affecting the achievement of tumor necrosis[J]. J Vasc Interv Radiol, 2005, 16(11): 1447-1457. DOI: 10.1097/01.RVI.90000172121.82299.38
    [32] POMPILI M, PACELLA CM, FRANCICA G, et al. Percutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation[J]. Eur J Radiol, 2010, 74(3): e6-e11. DOI: 10.1016/j.ejrad.2009.03.012
    [33] LENCIONI R, CIONI D, DELLA PINA C, et al. Hepatocellular carcinoma: New options for image-guided ablation[J]. J Hepatobiliary Pancreat Sci, 2010, 17(4): 399-403. DOI: 10.1007/s00534-009-0233-0
    [34] NARAYANAN G. Irreversible electroporation for treatment of liver cancer[J]. Gastroenterol Hepatol (N Y), 2011, 7(5): 313-316. http://www.ncbi.nlm.nih.gov/pubmed/21857833
    [35] MAOR E, IVORRA A, LEOR J, et al. The effect of irreversible electroporation on blood vessels[J]. Technol Cancer Res Treat, 2007, 6(4): 307-312. DOI: 10.1177/153303460700600407
    [36] CHARPENTIER KP, WOLF F, NOBLE L, et al. Irreversible electroporation of the liver and liver hilum in swine[J]. HPB (Oxford), 2011, 13(3): 168-173. DOI: 10.1111/j.1477-2574.2010.00261.x
    [37] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.05.009

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.05.009
    [38] CHEN MS, LI JQ, ZHENG Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg, 2006, 243(3): 321-328. DOI: 10.1097/01.sla.0000201480.65519.b8
    [39] FANG Y, CHEN W, LIANG X, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2014, 29(1): 193-200. DOI: 10.1111/jgh.12441
    [40] NG K, CHOK K, CHAN A, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma[J]. Br J Surg, 2017, 104(13): 1775-1784. DOI: 10.1002/bjs.10677
    [41] LAU WY, LAI EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: A systematic review[J]. Ann Surg, 2009, 249(1): 20-25. DOI: 10.1097/SLA.0b013e31818eec29
    [42] PENG ZW, ZHANG YJ, CHEN MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial[J]. J Clin Oncol, 2013, 31(4): 426-432. DOI: 10.1200/JCO.2012.42.9936
    [43] MORIMOTO M, NUMATA K, KONDOU M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: A randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization[J]. Cancer, 2010, 116(23): 5452-5460. DOI: 10.1002/cncr.25314
    [44] KAGAWA T, KOIZUMI J, KOJIMA S, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: Comparison with surgical resection[J]. Cancer, 2010, 116(15): 3638-3644. DOI: 10.1002/cncr.25142
  • 加载中
计量
  • 文章访问数:  66
  • HTML全文浏览量:  27
  • PDF下载量:  34
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-02-18
  • 修回日期:  2021-02-18
  • 刊出日期:  2021-03-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回